Veeva Systems posts strong Q2 revenue growth, beating expectations with 18% increase and solid cash flow.

Veeva Systems reported fiscal Q2 revenue of $928 million, marking an 18% year-over-year increase, alongside a 40% rise in GAAP operating income. The company retained 70% of its biopharma CRM subscription base and secured all four undecided top-20 accounts, signaling strong customer loyalty. Robust free cash flow and aggressive share buybacks support confidence in the business, with guidance indicating approximately 15% revenue growth for FY27. This performance highlights Veeva's accelerating fundamentals and growth potential going forward.

Veeva Systems shares are trading at USD 312.00 on Pluang as of Nov 02, 2026 16:31 WIB, slightly down by 0.31% in the last day. The stock's market capitalization stands at $50.67 billion, reflecting its significant presence in the technology sector. Investors typically hold VEEV shares for about 8 days on the platform, indicating moderate trading activity.